Sudeep Pharma Ltd. IPO

IPO Details
Bidding Date Nov 21, 2025	IPO Price Range ₹563 to ₹593 per share	IPO Size ₹895 Cr
Listing Exchange BSE, NSE	Listing Date Nov 28, 2025	Lot Size 25 Shares

Minimum Investment
₹14,825/25shares

IPO Timeline

Open DateNov 21, 2025

Close DateNov 25, 2025

Allotment FinalisationNov 26, 2025

Demat TransferNov 27, 2025

Refund InitiationNov 27, 2025

ListingNov 28, 2025

About Sudeep Pharma Ltd. IPO

Sudeep Pharma is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and are dedicated to contributing to the global healthcare ecosystem. The company leverages its in-house developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending to drive innovation in its operations. The company has established a presence in both, domestic and international markets, including key regions such as the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific. Sudeep Pharma is one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors, in terms of production capacity with a combined annual manufacturing capacity of 65,579 metric tons as of December 31, 2024 as per F&S Report.

Sudeep Pharma Ltd. IPO Subscription Status

Date	QIB	NII	Retail	Total
TBA	0	0	0	0
TBA	0	0	0	0

Cult.fit IPO Financial Status

Particulars (in Rs. Crores)	30 Jun 2025	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	922.26	717.17	513.87	420.11
Total Income	130.08	511.33	465.38	438.26
Profit After Tax	31.27	138.69	133.15	62.32
EBITDA	48.57	199.28	187.76	98.64
Net Worth	688.32	497.53	359.07	226.29
Reserves and Surplus	668.52	481.11	354.59	221.88
Total Borrowing	135.97	135.25	75.03	82.26

Sudeep Pharma Ltd. IPO SWOT Analysis

Strengths

Market leadership with a diversified product portfolio in a high barrier industry.
Distinguished global customer base with long-standing relationships with key customers.
Well-equipped and regulatory compliant manufacturing facilities.
Strong research and development capabilities.

Weaknesses

Failed audits or quality issues could result in lost orders and damage to their reputation.
Delays or setbacks in launching new products could hinder growth and reduce profitability.
Operational disruptions may arise from delays in regulatory or government approvals.
Dependence on few key customers, and losing them or facing reduced demand could negatively impact their business and finances.